Integrated Transcriptomic and DNA Methylation Analysis Reveals ITGB2-Mediated Immune Dysregulation in Polycystic Ovary Syndrome and Its Modulation by Rutin.

Peng Yi, Ying Cao, Yanru Zhou, Suqing Mao, Xianghong Fu

Abstract read

In one paragraph

Article in Reproductive sciences (Thousand Oaks, Calif.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Peng YiCenter of Reproductive Medicine, Quzhou People's Hospital, The Quzhou Affiliated Hospital, Wenzhou Medical University, Quzhou, Zhejiang, 324000, China. yipengqz@wmu.edu.cn.ORCID http://orcid.org/0009-0000-1832-1783

Ying CaoCenter of Reproductive Medicine, Quzhou People's Hospital, The Quzhou Affiliated Hospital, Wenzhou Medical University, Quzhou, Zhejiang, 324000, China.

Yanru ZhouCenter of Reproductive Medicine, Quzhou People's Hospital, The Quzhou Affiliated Hospital, Wenzhou Medical University, Quzhou, Zhejiang, 324000, China.

Suqing MaoCenter of Reproductive Medicine, Quzhou People's Hospital, The Quzhou Affiliated Hospital, Wenzhou Medical University, Quzhou, Zhejiang, 324000, China.

Xianghong FuCenter of Reproductive Medicine, Quzhou People's Hospital, The Quzhou Affiliated Hospital, Wenzhou Medical University, Quzhou, Zhejiang, 324000, China. qzfuxianghong@163.com.

Funding

Quzhou Municipal Bureau of Science and Technology of Zhejiang Province, China 2021Y012Quzhou Municipal Bureau of Science and Technology of Zhejiang Province, China 2022K54

6 · The paper itself

Abstract

objectivesTo identify immune-related molecular targets in polycystic ovary syndrome (PCOS) and evaluate the role of integrin beta-2 (ITGB2) and the potential modulation by rutin.

methodsFollicular fluid cytokines from 30 women with PCOS and 30 control women were profiled. Transcriptomic (GSE34526) and DNA methylation (GSE138573) data were integrated to identify overlapping genes, followed by functional enrichment analyses, protein-protein interaction (PPI), and molecular docking analyses. LPS-stimulated granulosa cells, in the presence or absence of ITGB2 overexpression and rutin treatment, were assessed for gene expression, viability, cytokine secretion, and NF-κB activation.

resultsWomen with PCOS had higher IL-5 but lower IL-1β and IL-12p70. ITGB2, ITGAM, and CD86 were upregulated and hypomethylated. Among these, ITGB2 bound rutin with the lowest energy (- 7.8 kcal/mol). Rutin reduced ITGB2 expression, restored viability, suppressed cytokine release, and inhibited NF-κB activation, even under ITGB2 overexpression.

conclusionITGB2 is associated with inflammatory responses in granulosa cells and may contribute to PCOS-related immune dysregulation via NF-κB activation. Rutin attenuates these inflammatory responses, supporting a potential involvement of the ITGB2/NF-κB axis as a therapeutic target. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

DNA methylationITGB2NF-κBPolycystic ovary syndromeRutin

Identifiers

PMID42576102

DOI10.1016/j.crfs.2022.07.007

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.